Published: 13 April 2016
Author(s): Xavier Humbert, Sophie Fedrizzi, Joachim Alexandre, Paolo-Emilio Puddu, Antoine Coquerel, Jean-Charles Robert, Lydia Guittet
Issue: April 2016
Section: Letter to the Editor

Angiotensin-converting enzyme inhibitors (ACEI) are widely used in the management of hypertension, heart failure, myocardial infarction, renal failure, and kidney diseases. ACEI produced a 10% reduction in all-cause mortality and a 12% reduction in cardiovascular mortality in hypertensive patients [1]. They represent the first-line therapy in cardiovascular protection in the group of renin angiotensin aldosterone system (RAAS). Generally, they are well-tolerated by most patients. However, cough is a well-known side effect with this drug class, and the cough can be severe enough to require medication discontinuation.


Stay informed on our latest news!


This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.